7 documents found, page 1 of 1
Hospitalization of symptomatic patients with heart failure and moderate to seve...
Ponikowski, Piotr; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Shahzeb Khan, Muhammad; Diek, Monika; Heinrich, Jutta; Geyer, MartinBackground: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. Objectives: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before ...
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgita...
Anker, Stefan D.; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Khan, Muhammad Shahzeb; Diek, Monika; Heinrich, Jutta; Geyer, MartinAim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results: The RESHAPE-HF...
Association between common cardiovascular risk factors and clinical phenotype i...
Lopes, Luis R.; Losi, Maria-Angela; Sheikh, Nabeel; Laroche, Cécile; Charron, Philippe; Gimeno, Juan; Kaski, Juan P.; Maggioni, Aldo P.; Tavazzi, LuigiAims: The interaction between common cardiovascular risk factors (CVRF) and hypertrophic cardiomyopathy (HCM) is poorly studied. We sought to explore the relation between CVRF and the clinical characteristics of patients with HCM enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy registry. Methods and results: 1739 patients with HCM were studied. The relation between hypertension (HT), di...
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Co...
Samuel, Michelle; Tardif, Jean-Claude; Khairy, Paul; Roubille, François; Waters, David D; Grégoire, Jean C; Pinto, Fausto J.; Maggioni, Aldo P.Aims: In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina leading to coronary revascularization. To asse...
Pharmacogenomics of the efficacy and safety of Colchicine in COLCOT
Dubé, Marie-Pierre; Legault, Marc-André; Lemaçon, Audrey; Lemieux Perreault, Louis-Philippe; Fouodjio, René; Waters, David D.; Kouz, SimonBackground: The randomized, placebo-controlled COLCOT (Colchicine Cardiovascular Outcomes Trial) has shown the benefits of colchicine 0.5 mg daily to lower the rate of ischemic cardiovascular events in patients with a recent myocardial infarction. Here, we conducted a post hoc pharmacogenomic study of COLCOT with the aim to identify genetic predictors of the efficacy and safety of treatment with colchicine. Met...
Time-to-treatment initiation of colchicine and cardiovascular outcomes after my...
Bouabdallaoui, Nadia; Tardif, Jean-Claude; Waters, David D.; Pinto, Fausto J.; Maggioni, Aldo P.; Diaz, Rafael; Berry, Colin; Koenig, WolfgangAims: The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the beneficial impact of colchicine. Methods and results: In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-treatment initiation was d...
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, Jean-Claude; Kouz, Simon; Waters, David D.; Bertrand, Olivier F.; Diaz, Rafael; Maggioni, Aldo P.; Pinto, Fausto J.; Ibrahim, Reda; Gamra, HabibBackground: Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. Methods: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly ...